GE HealthCare Technologies Inc. appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026, succeeding Jay Saccaro who stepped down for an expanded role outside the medical technology industry. George A. Newcomb will cease serving as interim CFO and continue as Controller and Chief Accounting Officer. Mr. Grogan joins from Xylem Inc., where he served as Executive Vice President and CFO since October 2023, previously holding similar roles at IDEX Corporation. His compensation package includes a $900,000 annual base salary, a target bonus equal to 100% of base salary, and an annual long-term incentive award valued at $3,300,000. Additionally, he will receive a $550,000 cash sign-on payment and a one-time equity award of restricted stock units valued at $4,000,000 to offset forfeited compensation from his prior employer. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions.

GE HealthCare Technologies Inc. filed a Form 8-K to provide recast unaudited historical financial information reflecting a change in reportable segments announced in the second quarter of 2026. The company combined its Imaging and Advanced Visualization Solutions businesses into a new operating segment, Advanced Imaging Solutions (AIS). GE HealthCare now reports three segments: AIS, Pharmaceutical Diagnostics (PDx), and Patient Care Solutions (PCS). Total revenues for the first quarter ended March 31, 2026, were $5.1 billion, with AIS contributing $3.64 billion, PDx $770 million, and PCS $704 million. Segment EBIT was $479 million for AIS, $197 million for PDx, and $10 million for PCS. The filing includes supplemental financial data to aid comparability but has no impact on previously reported consolidated financial statements. GE HealthCare Technologies Inc. operates in the medical technology industry, providing diagnostic imaging, pharmaceutical diagnostics, and patient care solutions.

GE HealthCare Technologies Inc. reported second quarter 2026 financial results on July 29, 2026. Total revenue increased 5.7% to $5.3 billion, driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions declined 13.3%. Diluted earnings per share rose 16.5% to $1.24, supported by a net income of $561 million and tariff refunds totaling $129 million. The company recorded record organic order growth of 11.1%, resulting in a book-to-bill ratio of 1.15 times and a backlog of $23.9 billion. GE HealthCare reaffirmed its full-year 2026 guidance, including adjusted EPS between $4.80 and $5.00. The company operates in the medical technology industry, designing and manufacturing diagnostic imaging systems, patient monitoring solutions, and pharmaceutical diagnostics.

GE HealthCare Technologies Inc. announced a CFO transition, with Jay Saccaro resigning as CFO effective August 14, 2026, and George Newcomb appointed as interim CFO. The company also reported preliminary second quarter 2026 results, projecting a 5.7% year-over-year revenue growth to $5.295 billion and 3.5% organic revenue growth. GE HealthCare is a global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions.